Slide 1: Simulations Plus, Inc. Second Quarter Fiscal Year 2014 Conference Call
Simulations Plus, Inc. (NASDAQ:SLP) Second Quarter Fiscal Year 2014 Conference Call and Webinar April 9, 2014 simulationsplus, inc, ¢
Slide 2: Safe Harbor Statement
Safe Harbor Statement With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause
Slide 3: Q2 FY14 Highlights
Q14 Highlights Three months ended 2/28/14: * 2Q14 compared to 2Q13: — 26! consecutive profitable quarter Sales were $3.081 million, a 1.2% decrease ($37K) from $3.118 million ‘Approximately $350K in revenues were delayed until 30114 as one of our larger customers decided to move a global renewal ord
Slide 4: Income Statement 2QFY14 vs 2QFY13
Income Statement 2QFY14 vs 2QFY13 ($ millions) Net sales Gross profit Gross profit margin SG8A R&D ‘Total operating expenses Income from operations Other income Income from operations before income taxes Net income Diluted earnings per share simulationsplus, inc. g
Slide 5: Six months ended 2/28/14 Highlights
4 Highlig' Six months ended 2/28/14: * 6moFY14 compared to 6moFY13: — Sales increased by $314,000 or 5.8% to $5.722 million from $5.408 million Gross profit increased 5.7% to $4.782 million from $4.523 million SG8A increased 21.8% to $2.175 million from $ 1.786 million ‘As a percent of revenues, SG&
Slide 6: Income Statement 6moFY14 vs 6moFY13
Income Statement 6moFY14 vs 6moFY13 ($ millions) eS ee Net sales 5.722 5.408 Gross profit 4.782 Gross profit margin 83.6% SG&A 2.175 R&D 0.516 Total operating expenses 2.691 Income from continuing operations 2.091 Other income 0.45 Income from operations before income taxes 2.136 Net income 1.495 Di
Slide 7: Revenues by Quarter
Revenues by Quarter (pro forma prior to 2012) $16 sta) $13} si si imulationsplus, inc.
Slide 8: Gross Profit by Fiscal Quarter
Gross Profit by Fiscal Quarter (pro forma prior to 2012)
Slide 9: EBITDA by Fiscal Quarter
EBITDA by Fiscal Quarter sus 51.48 $1.46) s129 a2 as 2009 2010 2011 = 2012 = 2019 2014
Slide 10: Net Income by Quarter
Net Income by Quarter (pro forma prior to 2012) $108 soot | 0.81 a2 as 2010 ©2011 =2012 =2013 =2014 simulations plus, inc, é
Slide 11: New Customers by Quarter
New Customers by Quarter | New record! 1 15 “4 | | | a 2010 2013 = 2014 simulationsplus, inc. @ oa
Slide 12: Selected Balance Sheet Items
Selected Balance Sheet Items ($ millions) Cash and cash equivalents Cash per share Total current assets Total assets Total current liabilities Total liabilities Current ratio Shareholders’ equity Total liabilities and shareholders’ equity Shareholders’ equity per diluted share *Cash as of today is $
Slide 13: Returning Cash to Shareholders
Returning Cash to Shareholders $13.24 $12. O— Sg? 51270 | $10.56 —_ “as of 492014 $197 red | | oom om om U6 Q4FY11 QIFY12 Q2FY12 Q3FY12 Q4FY12 QIFY13 Q2FY13 Q3FY13 Q4FY13 QIFY14 Q2FY14 mm DividendPaid sam Proceedsfrom Sale of Subsidiary + ®=Cash simulationsplus, inc. é
Slide 14: Simulations Plus Products & Services
Simulations Plus Products & Services Discovery Preclinical Clinical ADMET Predictor™ MedChem Studio™ ‘DDDPlus™| MedChem Designer™ Consulting Services & Collaborations _|simulationsplus,inc, é \ J
Slide 15: Product News
Product News Version 8.5 released Q4FY2013 + Unique precipitation model added + Infant PBPK physiologies added — pediatrics is high-interest area in FDA and industry + Added a built-in method for transporter in vitro-in vivo extrapolation + Added a number of additional built-in enzyme expression lev
Slide 16: Marketing and Sales Program
Marketing and Sales Program Conferences/Scientific Meetings continue to be primary source of leads + During Q2 we participated in 4 scientific meetings and conferences in the U.S. and Europe with 2 scientific posters and presentations Trainings and Workshops + Conducted 6 on-site training courses at
Slide 17: FDA Collaborations
FDA Collaborations * Center for Food Safety and Nutrition (CFSAN) Nearly through the third year of a 5-year renewable Research Collaboration Agreement (RCA) with CFSAN to provide model-building capabilities for a large number (>70,000) of substances that can be in foods as additives or contaminants,
Slide 18: NCE (New Chemical Entity) Project
NCE (New Chemical Entity) Project Cone Wie as target (Celebrex® target) for our second NCE project (first was malaria COX-1 also needs to be inhibited, but at a lesser level (Aspirin target) Designing single molecules that bind to two different targets is more challenging than hitting only one targe
Slide 19: Growth Opportunities
Growth Opportunities MembranePlus™- new software product to simulate in vitro permeability experiments + Similar concept to DDDPIus™ - unique capability in the industry Continued enhancement of current software products to expand coverage into new areas Dermal dosing module in GastroPlus™ + Addition
Slide 20: Summary
‘Summary For 2QFY14: - _ Revenues and earnings continued six-year-plus profitable trend - Delay of one large renewal order and one study contract had -$350,000 impact - both orders were received in the third quarter Continuing to Grow: - Three new Ph.D.s added in FY13 - One new Ph.D. started Monday,
Slide 21: simulationsplus, ine, g
simulationsplus, ine, g